FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vaccines (Basel) / Immunogenicity of Calvenza-03 EIV/EHV® Vaccine in Horse...
Vaccines2021; 9(2); 166; doi: 10.3390/vaccines9020166

Immunogenicity of Calvenza-03 EIV/EHV® Vaccine in Horses: Comparative In Vivo Study.

Abstract: Equine influenza (EI) is a highly contagious acute respiratory disease of equines that is caused mainly by the H3N8 subtype of influenza A virus. Vaccinating horses against EI is the most effective strategy to prevent the infection. The current study aimed to compare the kinetics of EI-specific humoral- and cell-mediated immunity (CMI) in horses receiving either identical or mixed vaccinations. Two groups of horses were previously (six months prior) vaccinated with either Calvenza 03 EIV EHV (G1) or Fluvac Innovator (G2) vaccine. Subsequently, both groups received a booster single dose of Calvenza 03 EIV EHV. Immune responses were assessed after 10 weeks using single radial hemolysis (SRH), virus neutralization (VN), and EliSpot assays. Our results revealed that Calvenza-03 EIV/EHV-immunized horses had significantly higher protective EI-specific SRH antibodies and VN antibodies. Booster immunization with Calvenza-03 EIV/EHV vaccine significantly stimulated cell-mediated immune response as evidenced by significant increase in interferon-γ-secreting peripheral blood mononuclear cells. In conclusion, Calvenza-03 EIV/EHV vaccine can be safely and effectively used for booster immunization to elicit optimal long persisting humoral and CMI responses even if the horses were previously immunized with a heterogeneous vaccine.
Get Full Text
Publication Date: 2021-02-17 PubMed ID: 33671378PubMed Central: PMC7922102DOI: 10.3390/vaccines9020166Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research investigates the effectiveness of the Calvenza-03 EIV/EHV vaccine in horses, specifically against equine influenza. The results indicate that horses vaccinated with the Calvenza-03 vaccine developed significantly stronger immune responses even when they had been previously given different vaccines.

Objective of the Research

The researchers sought to investigate the effectiveness of the Calvenza-03 EIV/EHV vaccine against equine influenza (EI). They aimed to achieve this objective by comparing the immune responses in horses who either received this vaccine only, or those who were previously given a different vaccine before receiving a booster dose of Calvenza-03 vaccine.

Methodology of the Research

  • Two groups of horses, previously vaccinated (six months before) with either Calvenza 03 EIV EHV (G1) or Fluvac Innovator (G2) vaccine, were chosen for this study.
  • Both groups received a single booster dose of Calvenza 03 EIV EHV.
  • After 10 weeks, immune responses were assessed using single radial hemolysis (SRH), virus neutralization (VN), and EliSpot assays.

Results of the Research

  • Horses immunized with Calvenza-03 EIV/EHV had significantly higher EI-specific SRH antibodies and VN antibodies compared to those immunized with a different initial vaccine.
  • The booster immunization with the Calvenza-03 EIV/EHV vaccine significantly increased cell-mediated immune responses, evident by a significant rise in interferon-γ-secreting peripheral blood mononuclear cells.

Conclusion

It was concluded that the Calvenza-03 EIV/EHV vaccine is safe and effective to be used as a booster vaccine to stimulate effective, long-lasting humoral and cell-mediated immunity, even in horses previously given a different type of vaccine. This can potentially improve practices in the prevention and control of equine influenza.

Cite This Article

APA
Pavulraj S, Bergmann T, Trombetta CM, Marchi S, Montomoli E, Alami SSE, Ragni-Alunni R, Osterrieder N, Azab W. (2021). Immunogenicity of Calvenza-03 EIV/EHV® Vaccine in Horses: Comparative In Vivo Study. Vaccines (Basel), 9(2), 166. https://doi.org/10.3390/vaccines9020166

Publication

Vaccines
ISSN: 2076-393X
NlmUniqueID: 101629355
Country: Switzerland
Language: English
Volume: 9
Issue: 2
PII: 166

Researcher Affiliations

Pavulraj, Selvaraj
  • Institut für Virologie, Robert von Ostertag-Haus, Zentrum für Infektionsmedizin, Freie Universität Berlin, Robert-von-Ostertag-Str. 7-13, 14163 Berlin, Germany.
Bergmann, Tobias
  • Institut für Virologie, Robert von Ostertag-Haus, Zentrum für Infektionsmedizin, Freie Universität Berlin, Robert-von-Ostertag-Str. 7-13, 14163 Berlin, Germany.
Trombetta, Claudia Maria
  • Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.
Marchi, Serena
  • Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.
Montomoli, Emanuele
  • Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.
  • VisMederi srl, 53100 Siena, Italy.
Alami, Sidi Sefiane El
  • AL-REEF Stable, Abu Dhabi P.O. Box 5151, United Arab Emirates.
Ragni-Alunni, Roberto
  • Equine Marketing Division, Boehringer Ingelheim META, Dubai P.O. Box 507066, United Arab Emirates.
Osterrieder, Nikolaus
  • Institut für Virologie, Robert von Ostertag-Haus, Zentrum für Infektionsmedizin, Freie Universität Berlin, Robert-von-Ostertag-Str. 7-13, 14163 Berlin, Germany.
  • Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Kowloon Tong, Hong Kong 999077, China.
Azab, Walid
  • Institut für Virologie, Robert von Ostertag-Haus, Zentrum für Infektionsmedizin, Freie Universität Berlin, Robert-von-Ostertag-Str. 7-13, 14163 Berlin, Germany.

Conflict of Interest Statement

At the time of trial R.R.A. was Marketing Manager at Boehringer Ingelheim META. R.R.A. designed the study and proceeded to the collection and shipment of the blinded samples to FU Berlin, he also contributed in the writing of the manuscript. The other authors declare no conflict of interest.

References

This article includes 39 references
  1. Paillot R, Prowse L, Montesso F, Stewart B, Jordon L, Newton JR, Gilkerson JR. Duration of equine influenza virus shedding and infectivity in immunised horses after experimental infection with EIV A/eq2/Richmond/1/07.. Vet Microbiol 2013 Sep 27;166(1-2):22-34.
    doi: 10.1016/j.vetmic.2013.04.027pubmed: 23769636google scholar: lookup
  2. Paillot R, Pitel PH, Pronost S, Legrand L, Fougerolle S, Jourdan M, Marcillaud-Pitel C. Florida clade 1 equine influenza virus in France.. Vet Rec 2019 Jan 19;184(3):101.
    doi: 10.1136/vr.l1203pubmed: 30655407google scholar: lookup
  3. Mena J, Brito B, Moreira R, Tadich T, González I, Cruces J, Ortega R, van Bakel H, Rathnasinghe R, Pizarro-Lucero J, Medina R, Neira V. Reemergence of H3N8 Equine Influenza A virus in Chile, 2018.. Transbound Emerg Dis 2018 Dec;65(6):1408-1415.
    doi: 10.1111/tbed.12984pubmed: 30054993google scholar: lookup
  4. Fougerolle S, Fortier C, Legrand L, Jourdan M, Marcillaud-Pitel C, Pronost S, Paillot R. Success and Limitation of Equine Influenza Vaccination: The First Incursion in a Decade of a Florida Clade 1 Equine Influenza Virus that Shakes Protection Despite High Vaccine Coverage.. Vaccines (Basel) 2019 Nov 2;7(4).
    doi: 10.3390/vaccines7040174pmc: PMC6963532pubmed: 31684097google scholar: lookup
  5. Yang H, Xiao Y, Meng F, Sun F, Chen M, Cheng Z, Chen Y, Liu S, Chen H. Emergence of H3N8 equine influenza virus in donkeys in China in 2017.. Vet Microbiol 2018 Feb;214:1-6.
    doi: 10.1016/j.vetmic.2017.11.033pubmed: 29408020google scholar: lookup
  6. Miño S, Mojsiejczuk L, Guo W, Zhang H, Qi T, Du C, Zhang X, Wang J, Campos R, Wang X. Equine Influenza Virus in Asia: Phylogeographic Pattern and Molecular Features Reveal Circulation of an Autochthonous Lineage.. J Virol 2019 Jul 1;93(13).
    doi: 10.1128/JVI.00116-19pmc: PMC6580976pubmed: 31019053google scholar: lookup
  7. Shittu I, Meseko CA, Sulaiman LP, Inuwa B, Mustapha M, Zakariya PS, Muhammad AA, Muhammad U, Atuman YJ, Barde IJ, Zecchin B, Quaranta EG, Shamaki D, Alabi O, Monne I, Fusaro A, Joannis TM. Fatal multiple outbreaks of equine influenza H3N8 in Nigeria, 2019: The first introduction of Florida clade 1 to West Africa.. Vet Microbiol 2020 Sep;248:108820.
    doi: 10.1016/j.vetmic.2020.108820pubmed: 32891950google scholar: lookup
  8. Sreenivasan CC, Jandhyala SS, Luo S, Hause BM, Thomas M, Knudsen DEB, Leslie-Steen P, Clement T, Reedy SE, Chambers TM, Christopher-Hennings J, Nelson E, Wang D, Kaushik RS, Li F. Phylogenetic Analysis and Characterization of a Sporadic Isolate of Equine Influenza A H3N8 from an Unvaccinated Horse in 2015.. Viruses 2018 Jan 11;10(1).
    doi: 10.3390/v10010031pmc: PMC5795444pubmed: 29324680google scholar: lookup
  9. Rash A, Morton R, Woodward A, Maes O, McCauley J, Bryant N, Elton D. Evolution and Divergence of H3N8 Equine Influenza Viruses Circulating in the United Kingdom from 2013 to 2015.. Pathogens 2017 Feb 8;6(1).
    doi: 10.3390/pathogens6010006pmc: PMC5371894pubmed: 28208721google scholar: lookup
  10. Olguin Perglione C, Golemba MD, Torres C, Barrandeguy M. Molecular Epidemiology and Spatio-Temporal Dynamics of the H3N8 Equine Influenza Virus in South America.. Pathogens 2016 Oct 16;5(4).
    doi: 10.3390/pathogens5040061pmc: PMC5198161pubmed: 27754468google scholar: lookup
  11. Daly JM, Newton JR, Mumford JA. Current perspectives on control of equine influenza.. Vet Res 2004 Jul-Aug;35(4):411-23.
    doi: 10.1051/vetres:2004023pubmed: 15236674google scholar: lookup
  12. Reemers S, Sonnemans D, Horspool L, van Bommel S, Cao Q, van de Zande S. Determining Equine Influenza Virus Vaccine Efficacy-The Specific Contribution of Strain Versus Other Vaccine Attributes.. Vaccines (Basel) 2020 Sep 3;8(3).
    doi: 10.3390/vaccines8030501pmc: PMC7564743pubmed: 32899189google scholar: lookup
  13. Pavulraj S, Virmani N, Bera BC, Joshi A, Anand T, Virmani M, Singh R, Singh RK, Tripathi BN. Immunogenicity and protective efficacy of inactivated equine influenza (H3N8) virus vaccine in murine model.. Vet Microbiol 2017 Oct;210:188-196.
    doi: 10.1016/j.vetmic.2017.08.013pubmed: 29103691google scholar: lookup
  14. Gamoh K, Nakamura S. Update of inactivated equine influenza vaccine strain in Japan.. J Vet Med Sci 2017 Mar 23;79(3):649-653.
    doi: 10.1292/jvms.16-0558pmc: PMC5383192pubmed: 28163276google scholar: lookup
  15. Paillot R, Prowse L, Montesso F, Huang CM, Barnes H, Escala J. Whole inactivated equine influenza vaccine: Efficacy against a representative clade 2 equine influenza virus, IFNgamma synthesis and duration of humoral immunity.. Vet Microbiol 2013 Mar 23;162(2-4):396-407.
    doi: 10.1016/j.vetmic.2012.10.019pubmed: 23146168google scholar: lookup
  16. Paillot R, Rash NL, Garrett D, Prowse-Davis L, Montesso F, Cullinane A, Lemaitre L, Thibault JC, Wittreck S, Dancer A. How to Meet the Last OIE Expert Surveillance Panel Recommendations on Equine Influenza (EI) Vaccine Composition: A Review of the Process Required for the Recombinant Canarypox-Based EI Vaccine.. Pathogens 2016 Nov 25;5(4).
    doi: 10.3390/pathogens5040064pmc: PMC5198164pubmed: 27897990google scholar: lookup
  17. Entenfellner J, Gahan J, Garvey M, Walsh C, Venner M, Cullinane A. Response of Sport Horses to Different Formulations of Equine Influenza Vaccine.. Vaccines (Basel) 2020 Jul 10;8(3).
    doi: 10.3390/vaccines8030372pmc: PMC7563521pubmed: 32664411google scholar: lookup
  18. Chambers TM, Holland RE, Tudor LR, Townsend HG, Cook A, Bogdan J, Lunn DP, Hussey S, Whitaker-Dowling P, Youngner JS, Sebring RW, Penner SJ, Stiegler GL. A new modified live equine influenza virus vaccine: phenotypic stability, restricted spread and efficacy against heterologous virus challenge.. Equine Vet J 2001 Nov;33(7):630-6.
    doi: 10.2746/042516401776249291pubmed: 11770982google scholar: lookup
  19. Youngner JS, Whitaker-Dowling P, Chambers TM, Rushlow KE, Sebring R. Derivation and characterization of a live attenuated equine influenza vaccine virus.. Am J Vet Res 2001 Aug;62(8):1290-4.
    doi: 10.2460/ajvr.2001.62.1290pubmed: 11497453google scholar: lookup
  20. Tabynov K, Kydyrbayev Z, Ryskeldinova S, Assanzhanova N, Kozhamkulov Y, Inkarbekov D, Sansyzbay A. Safety and immunogenicity of a novel cold-adapted modified-live equine influenza virus vaccine.. Aust Vet J 2014 Nov;92(11):450-7.
    doi: 10.1111/avj.12248pubmed: 25348146google scholar: lookup
  21. Blanco-Lobo P, Rodriguez L, Reedy S, Oladunni FS, Nogales A, Murcia PR, Chambers TM, Martinez-Sobrido L. A Bivalent Live-Attenuated Vaccine for the Prevention of Equine Influenza Virus.. Viruses 2019 Oct 11;11(10).
    doi: 10.3390/v11100933pmc: PMC6832603pubmed: 31614538google scholar: lookup
  22. Mathew MK, Virmani N, Bera BC, Anand T, Kumar R, Balena V, Sansanwal R, Pavulraj S, Sundaram K, Virmani M, Tripathi BN. Protective efficacy of inactivated reverse genetics based equine influenza vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine model.. J Vet Med Sci 2019 Dec 18;81(12):1753-1762.
    doi: 10.1292/jvms.19-0399pmc: PMC6943333pubmed: 31656240google scholar: lookup
  23. Gildea S, Garvey M, Lyons P, Lyons R, Gahan J, Walsh C, Cullinane A. Multifocal Equine Influenza Outbreak with Vaccination Breakdown in Thoroughbred Racehorses.. Pathogens 2018 Apr 17;7(2).
    doi: 10.3390/pathogens7020043pmc: PMC6027538pubmed: 29673169google scholar: lookup
  24. Daly JM, Elton D. Potential of a sequence-based antigenic distance measure to indicate equine influenza vaccine strain efficacy.. Vaccine 2013 Dec 9;31(51):6043-5.
    doi: 10.1016/j.vaccine.2013.06.070pubmed: 23831320google scholar: lookup
  25. Daly JM, MacRae S, Newton JR, Wattrang E, Elton DM. Equine influenza: a review of an unpredictable virus.. Vet J 2011 Jul;189(1):7-14.
    doi: 10.1016/j.tvjl.2010.06.026pubmed: 20685140google scholar: lookup
  26. Mumford J, Wood JM, Scott AM, Folkers C, Schild GC. Studies with inactivated equine influenza vaccine. 2. Protection against experimental infection with influenza virus A/equine/Newmarket/79 (H3N8).. J Hyg (Lond) 1983 Jun;90(3):385-95.
    doi: 10.1017/S0022172400029016pmc: PMC2134271pubmed: 6306098google scholar: lookup
  27. Mumford JA, Wood JM, Folkers C, Schild GC. Protection against experimental infection with influenza virus A/equine/Miami/63 (H3N8) provided by inactivated whole virus vaccines containing homologous virus.. Epidemiol Infect 1988 Jun;100(3):501-10.
    doi: 10.1017/S0950268800067236pmc: PMC2249356pubmed: 2837409google scholar: lookup
  28. Mumford JA, Wood J. Establishing an acceptability threshold for equine influenza vaccines.. Dev Biol Stand 1992;79:137-46.
    pubmed: 1286748
  29. Holmes MA, Townsend HG, Kohler AK, Hussey S, Breathnach C, Barnett C, Holland R, Lunn DP. Immune responses to commercial equine vaccines against equine herpesvirus-1, equine influenza virus, eastern equine encephalomyelitis, and tetanus.. Vet Immunol Immunopathol 2006 May 15;111(1-2):67-80.
    doi: 10.1016/j.vetimm.2006.01.010pubmed: 16476488google scholar: lookup
  30. Paillot R, Kydd JH, MacRae S, Minke JM, Hannant D, Daly JM. New assays to measure equine influenza virus-specific Type 1 immunity in horses.. Vaccine 2007 Oct 16;25(42):7385-98.
    doi: 10.1016/j.vaccine.2007.08.033pubmed: 17881098google scholar: lookup
  31. Equine Influenza. [(accessed on 17 February 2021)]; Available online: https://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/3.05.07_EQ_INF.pdf.
  32. Morley PS, Bogdan JR, Townsend HG, Haines DM. The effect of changing single radial hemolysis assay method when quantifying influenza A antibodies in serum.. Vet Microbiol 1995 Apr;44(1):101-10.
    doi: 10.1016/0378-1135(94)00111-9pubmed: 7667901google scholar: lookup
  33. Tangri S, Ishioka GY, Huang X, Sidney J, Southwood S, Fikes J, Sette A. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide.. J Exp Med 2001 Sep 17;194(6):833-46.
    doi: 10.1084/jem.194.6.833pmc: PMC2195959pubmed: 11560998google scholar: lookup
  34. Paillot R. A Systematic Review of Recent Advances in Equine Influenza Vaccination.. Vaccines (Basel) 2014 Nov 14;2(4):797-831.
    doi: 10.3390/vaccines2040797pmc: PMC4494246pubmed: 26344892google scholar: lookup
  35. Gildea S, Quinlivan M, Murphy BA, Cullinane A. Humoral response and antiviral cytokine expression following vaccination of thoroughbred weanlings--a blinded comparison of commercially available vaccines.. Vaccine 2013 Oct 25;31(45):5216-22.
    doi: 10.1016/j.vaccine.2013.08.083pubmed: 24021309google scholar: lookup
  36. Dilai M, Piro M, El Harrak M, Fougerolle S, Dehhaoui M, Dikrallah A, Legrand L, Paillot R, Fassi Fihri O. Impact of Mixed Equine Influenza Vaccination on Correlate of Protection in Horses.. Vaccines (Basel) 2018 Oct 4;6(4).
    doi: 10.3390/vaccines6040071pmc: PMC6313876pubmed: 30287762google scholar: lookup
  37. Yamanaka T, Nemoto M, Bannai H, Tsujimura K, Matsumura T, Kokado H, Gildea S, Cullinane A. Neutralization antibody response to booster/priming immunization with new equine influenza vaccine in Japan.. J Vet Med Sci 2018 Mar 2;80(2):382-386.
    doi: 10.1292/jvms.17-0538pmc: PMC5836781pubmed: 29237998google scholar: lookup
  38. Paillot R, Kydd JH, Sindle T, Hannant D, Edlund Toulemonde C, Audonnet JC, Minke JM, Daly JM. Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus.. Vet Immunol Immunopathol 2006 Aug 15;112(3-4):225-33.
    doi: 10.1016/j.vetimm.2006.02.007pubmed: 16621023google scholar: lookup
  39. Bryant NA, Paillot R, Rash AS, Medcalf E, Montesso F, Ross J, Watson J, Jeggo M, Lewis NS, Newton JR, Elton DM. Comparison of two modern vaccines and previous influenza infection against challenge with an equine influenza virus from the Australian 2007 outbreak.. Vet Res 2010 Mar-Apr;41(2):19.
    doi: 10.1051/vetres/2009067pmc: PMC2790087pubmed: 19863903google scholar: lookup

Citations

This article has been cited 5 times.
  1. Wasik BR, Rothschild E, Voorhees IEH, Reedy SE, Murcia PR, Pusterla N, Chambers TM, Goodman LB, Holmes EC, Kile JC, Parrish CR. Understanding the divergent evolution and epidemiology of H3N8 influenza viruses in dogs and horses. Virus Evol 2023;9(2):vead052.
    doi: 10.1093/ve/vead052pubmed: 37692894google scholar: lookup
  2. Lee DH, Lee EB, Seo JP, Ko EJ. Evaluation of concurrent vaccinations with recombinant canarypox equine influenza virus and inactivated equine herpesvirus vaccines. J Anim Sci Technol 2022 May;64(3):588-598.
    doi: 10.5187/jast.2022.e30pubmed: 35709134google scholar: lookup
  3. Oladunni FS, Oseni SO, Martinez-Sobrido L, Chambers TM. Equine Influenza Virus and Vaccines. Viruses 2021 Aug 20;13(8).
    doi: 10.3390/v13081657pubmed: 34452521google scholar: lookup
  4. Amodeo D, Marchi S, Fiaschi L, Raucci L, Biba C, Salvestroni V, Trombetta CM, Manini I, Zazzi M, Montomoli E, Vicenti I, Cevenini G, Messina G. Analysis of the SARS-CoV-2 inactivation mechanism using violet-blue light (405 nm). Appl Environ Microbiol 2025 Jun 18;91(6):e0040325.
    doi: 10.1128/aem.00403-25pubmed: 40366184google scholar: lookup
  5. Atwa AS, Gomaa L, Elmenofy W, Amer HM, Ahmed BM. Expression of recombinant Florida clade 2 hemagglutinin in baculovirus expression system: A step for subunit vaccine development against H3N8 equine influenza virus. Open Vet J 2024 Jan;14(1):350-359.
    doi: 10.5455/OVJ.2024.v14.i1.32pubmed: 38633177google scholar: lookup
Subscribe to our newsletter
Join 99,359 horse owners like you who receive our email updates on horse health and nutrition.